WO2006093957A3 - Blood soluble drag reducing hyaluronic acid - Google Patents

Blood soluble drag reducing hyaluronic acid Download PDF

Info

Publication number
WO2006093957A3
WO2006093957A3 PCT/US2006/007066 US2006007066W WO2006093957A3 WO 2006093957 A3 WO2006093957 A3 WO 2006093957A3 US 2006007066 W US2006007066 W US 2006007066W WO 2006093957 A3 WO2006093957 A3 WO 2006093957A3
Authority
WO
WIPO (PCT)
Prior art keywords
hyaluronic acid
drag reducing
blood flow
increase
blood soluble
Prior art date
Application number
PCT/US2006/007066
Other languages
French (fr)
Other versions
WO2006093957A2 (en
Inventor
Kipling Thacker
Marina Kameneva
Original Assignee
Lifecore Biomedical Inc
Univ Pittsburgh
Kipling Thacker
Marina Kameneva
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/364,566 external-priority patent/US20070032451A1/en
Priority claimed from US11/364,577 external-priority patent/US20070032452A1/en
Application filed by Lifecore Biomedical Inc, Univ Pittsburgh, Kipling Thacker, Marina Kameneva filed Critical Lifecore Biomedical Inc
Priority to EP06736388A priority Critical patent/EP1858529A2/en
Publication of WO2006093957A2 publication Critical patent/WO2006093957A2/en
Publication of WO2006093957A3 publication Critical patent/WO2006093957A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

The use of hyaluronic acid and physiologically acceptable salts thereof as drag reducing agents is described. The compositions of the invention can be used to increase aortic blood flow, increase arterial blood flow, increase venous blood flow, decrease blood pressure, decrease peripheral vascular resistance, diminish the development of atherosclerosis, and/or prevent lethality of hemorrhagic shock.
PCT/US2006/007066 2005-02-28 2006-02-28 Blood soluble drag reducing hyaluronic acid WO2006093957A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP06736388A EP1858529A2 (en) 2005-02-28 2006-02-28 Blood soluble drag reducing hyaluronic acid

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US65711905P 2005-02-28 2005-02-28
US60/657,119 2005-02-28
US11/364,566 US20070032451A1 (en) 2005-02-28 2006-02-27 Blood soluble drag reducing hyaluronic acid
US11/364,577 US20070032452A1 (en) 2005-02-28 2006-02-27 Blood soluble drag reducing hyaluronic acid
US11/364,577 2006-02-27
US11/364,566 2006-02-27

Publications (2)

Publication Number Publication Date
WO2006093957A2 WO2006093957A2 (en) 2006-09-08
WO2006093957A3 true WO2006093957A3 (en) 2006-12-21

Family

ID=36843283

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/007066 WO2006093957A2 (en) 2005-02-28 2006-02-28 Blood soluble drag reducing hyaluronic acid

Country Status (2)

Country Link
EP (1) EP1858529A2 (en)
WO (1) WO2006093957A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112972490B (en) * 2021-03-04 2022-02-18 中国人民解放军军事科学院军事医学研究院 Application of hyaluronic acid in preparing medicine for preventing or treating iron death related diseases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5576072A (en) * 1995-02-01 1996-11-19 Schneider (Usa), Inc. Process for producing slippery, tenaciously adhering hydrogel coatings containing a polyurethane-urea polymer hydrogel commingled with at least one other, dissimilar polymer hydrogel
US5585361A (en) * 1994-06-07 1996-12-17 Genzyme Corporation Methods for the inhibition of platelet adherence and aggregation
US5817642A (en) * 1991-07-03 1998-10-06 Hyal Pharmaceutical Corporation Clearing of atherosclerosis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817642A (en) * 1991-07-03 1998-10-06 Hyal Pharmaceutical Corporation Clearing of atherosclerosis
US5585361A (en) * 1994-06-07 1996-12-17 Genzyme Corporation Methods for the inhibition of platelet adherence and aggregation
US5576072A (en) * 1995-02-01 1996-11-19 Schneider (Usa), Inc. Process for producing slippery, tenaciously adhering hydrogel coatings containing a polyurethane-urea polymer hydrogel commingled with at least one other, dissimilar polymer hydrogel

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHAI S ET AL: "A component of the diabetic angiopathy - hyaluronic acid - promotes the development of atherosclerosis", DIABETOLOGIA, vol. 47, no. Suppl. 1, August 2004 (2004-08-01), & 40TH ANNUAL MEETING OF THE EUROPEAN-ASSOCIATION-FOR-THE-STUDY-OF-DIAB ETES; MUNICH, GERMANY; SEPTEMBER 05 -09, 2004, pages A426, XP009071682, ISSN: 0012-186X *
KAMENEVA M V ET AL: "BLOOD SOLUBLE DRAG-REDUCING POLYMERS PREVENT LETHALITY FROM HEMORRHAGIC SHOCK IN ACUTE ANIMAL EXPERIMENTS", BIORHEOLOGY, ELSEVIER SCIENCE LTD., OXFORD, GB, vol. 41, 2004, pages 53 - 64, XP008061910, ISSN: 0006-355X *
SAWCHUK A P ET AL: "Drag reducing polymers may decrease atherosclerosis by increasing shear in areas normally exposed to low shear stress", JOURNAL OF VASCULAR SURGERY 1999 UNITED STATES, vol. 30, no. 4, 1999, pages 761 - 764, XP002396807, ISSN: 0741-5214 *

Also Published As

Publication number Publication date
WO2006093957A2 (en) 2006-09-08
EP1858529A2 (en) 2007-11-28

Similar Documents

Publication Publication Date Title
WO2005117858A3 (en) Compositions comprising nebivolol
WO2007002572A3 (en) Nattokinase for reducing whole blood viscosity
DE602006017057D1 (en) DEHYDRACETIC ACID COMPOSITIONS WITH LOW PH
ATE464057T1 (en) BUFFERED DIALYSIS SOLUTION
WO2014141284A3 (en) Renal pump
WO2005009398A3 (en) Tetracyclic benzamide derivatives and methods of use thereof
WO2005079797A3 (en) Hyperlipemia therapeutic agent comprising pitavastatins and eicosapentaenoic acid
NZ597757A (en) Aqueous insulin preparations containing methionine
WO2006130174A3 (en) Compositions comrising nebivolol
WO2007089577A3 (en) Method of reversing, preventing, delaying or stabilizing soft tissue calcification
EP2070509A3 (en) The use of Myrica gale oil
CA2634419C (en) Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
EA200800762A1 (en) PREVENTION OF HYPOTENCY AND STABILIZATION OF BLOOD PRESSURE IN HEMODIALYSIS PATIENTS
WO2006047466A3 (en) Ophthamological drugs
MX2009008166A (en) Method for decreasing inflammation and stress in a mammal using glucose antimetaboltes, avocado or avocado extracts.
WO2008044217A3 (en) 2-aminocarbonyl-pyridine derivatives
WO2008088537A3 (en) Stent with a coating for delivering a therapeutic agent
WO2005113016A3 (en) Modulation of glucose-6-phosphatase translocase expression
WO2009022417A1 (en) Peritoneal dialysate
WO2009004629A3 (en) A method for decreasing symptoms of alcohol consumption
WO2007038768A3 (en) Method for lowering blood pressure in pre-hypertensive individuals and/or individuals with metabolic syndrome
WO2007104641A3 (en) Super-absorber having improved smell-inhibition
WO2009086207A3 (en) Compositions and methods for joining non-conjoined lumens
WO2007145823A3 (en) Nasal appliance
WO2008058358A3 (en) Descriptive report of the patent of invention of the medicament 'rosuvastatin + metformin' in combined form for cardiovascular diseases.

Legal Events

Date Code Title Description
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006736388

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)